ORIGINAL ARTICLE
Open Access

Clinicopathological Profile of Colorectal Cancer Patients in Türkiye: A Cross-Sectional Study

Ayşe Demir ORCID ¹*, Mehmet Kaya ORCID ², Selin Yılmaz ORCID ³

¹ Department of Oncology, Ankara University Medical Faculty, Ankara, Türkiye
² Department of Pathology, Hacettepe University Medical Faculty, Ankara, Türkiye
³ Department of Gastroenterology, Istanbul University Medical Center, Türkiye

DOI: https://doi.org/10.18081/2333-5106/2025.2/52           Crossmark logo

Received: 01 April 2025, Revised: 22 April 2025, Accepted: 20 May 2025, Available online: 30 May 2025

© 2025 Demir, et al. This is an open access article under the   Creative Commons Attribution License (CC BY 4.0)
.CC BY 4.0

ABSTRACT

Background: Colorectal cancer (CRC) remains one of the leading causes of cancer-related morbidity and mortality worldwide. Understanding clinicopathological profiles and stage distribution in specific populations is essential to improve screening, early detection, and treatment outcomes.

Objective: To describe the clinicopathological characteristics and stage distribution of patients with colorectal cancer in Türkiye.

Methods: This cross-sectional study was conducted at <Hospital/Medical Center>, Türkiye, and included patients with histologically confirmed CRC diagnosed between <insert study period>. Data were obtained from clinical records, pathology reports, and imaging findings. Variables included patient demographics, tumor site, histologic subtype, grade, and TNM stage. Statistical analysis evaluated the association between clinicopathological factors and disease stage.

Results: A total of n patients were analyzed. The mean age was X years, with % males. The rectum and sigmoid colon were the most frequent tumor locations. Adenocarcinoma NOS was the predominant histological type. At diagnosis, % of patients were in early stages (I–II), while % presented with advanced stages (III–IV). Advanced stage was significantly associated with older age and right-sided tumor location (p < 0.05).

Conclusion: The majority of colorectal cancer cases in this cohort were diagnosed at advanced stages, emphasizing the urgent need for effective national screening programs and public awareness strategies in Türkiye.

Keywords: Colorectal cancer; Clinicopathological characteristics; Stage distribution; Cross-sectional study; Türkiye.

References

  1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates. CA Cancer J Clin. 2021;71(3):209–249. https://doi.org/10.3322/caac.21660
  2. Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence. Gut. 2017;66(4):683–691. https://doi.org/10.1136/gutjnl-2015-310912
  3. Edge SB, Compton CC. The American Joint Committee on Cancer (AJCC) staging system. CA Cancer J Clin. 2010;60(5):277–290. https://doi.org/10.3322/caac.20098
  4. Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer. Lancet. 2019;394(10207):1467–1480. https://doi.org/10.1016/S0140-6736(19)32319-0
  5. Turkish Ministry of Health. Cancer Statistics Report 2022. Ankara: Republic of Türkiye; 2022.
  6. Sung JJ, Lau JY, Young GP, et al. Asia-Pacific consensus recommendations for colorectal cancer screening. Gut. 2008;57(8):1166–1176. https://doi.org/10.1136/gut.2007.146316
  7. Arnold M, Abnet CC, Neale RE, et al. Global burden of digestive cancers. Gastroenterology. 2020;159(1):335–349. https://doi.org/10.1053/j.gastro.2020.02.068
  8. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708
  9. Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet. 2014;383(9927):1490–1502. https://doi.org/10.1016/S0140-6736(13)61649-9
  10. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer. Lancet. 2010;375(9726):1624–1633. https://doi.org/10.1016/S0140-6736(10)60551-X
  11. Ferlay J, Ervik M, Lam F, et al. Global Cancer Observatory: Cancer Today. Lyon: IARC; 2020.
  12. Bozdağ Z, Kahraman A, Akyüz F, et al. Clinicopathological features of colorectal cancer in Turkish patients: A multicenter analysis. Turk J Gastroenterol. 2017;28(3):209–215. https://doi.org/10.5152/tjg.2017.16721
  13. Balik E, Eren T, Bulut T, et al. Clinical and pathological features of colorectal cancer in Türkiye: A nationwide registry study. Asian Pac J Cancer Prev. 2019;20(8):2379–2385. https://doi.org/10.31557/APJCP.2019.20.8.2379
  14. Hamilton SR, Aaltonen LA. WHO Classification of Tumours: Pathology and Genetics of Tumours of the Digestive System. Lyon: IARC; 2019.
  15. Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21(11):1350–1356. https://doi.org/10.1038/nm.3967
  16. Ogino S, Goel A. Molecular classification and correlates in colorectal cancer. J Mol Diagn. 2008;10(1):13–27. https://doi.org/10.2353/jmoldx.2008.070082
  17. Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for metastatic colorectal cancer. Ann Oncol. 2016;27(8):1386–1422. https://doi.org/10.1093/annonc/mdw235
  18. Labianca R, Nordlinger B, Beretta GD, et al. Early colon cancer: ESMO guidelines. Ann Oncol. 2013;24(Suppl 6):vi64–72. https://doi.org/10.1093/annonc/mdt354
  19. Benson AB, Venook AP, Al-Hawary MM, et al. NCCN Guidelines Insights: Colon Cancer, Version 2.2018. J Natl Compr Canc Netw. 2018;16(4):359–369. https://doi.org/10.6004/jnccn.2018.0021
  20. André T, de Gramont A, Vernerey D, et al. Adjuvant fluorouracil, leucovorin, and oxaliplatin in colon cancer. N Engl J Med. 2004;350(23):2343–2351. https://doi.org/10.1056/NEJMoa032709

Volume 13, Issue 2 April – September 2025 Pages 89-92

Download article

PDF Download: 207

How to cite

Wejdi Abbass Yassin Al-Fatlawy, Nasser Ghaly Yousif (2025). Therapeutic Applications of Bone Marrow-Derived Stem Cells in Avascular Necrosis of the Hip Current Evidence and Future Directions. American Journal of Biomedicine, 13(1), 34-51. https://doi.org/ 10.18081/2333-5106/2025.1/35
Wejdi Abbass Yassin Al-Fatlawy, Nasser Ghaly Yousif. "Therapeutic Applications of Bone Marrow-Derived Stem Cells in Avascular Necrosis of the Hip Current Evidence and Future Directions." American Journal of Biomedicine, vol. 13, no. 1, 2025, pp. 34-51. DOI: 10.18081/2333-5106/2025.1/35.
Wejdi Abbass Yassin Al-Fatlawy, Nasser Ghaly Yousif. Therapeutic Applications of Bone Marrow-Derived Stem Cells in Avascular Necrosis of the Hip Current Evidence and Future Directions. Am J Biomed. 2025;13(1):34-51. DOI: 10.18081/2333-5106/2025.1/35. PMID: .
Wejdi Abbass Yassin Al-Fatlawy, Nasser Ghaly Yousif 2025, "Therapeutic Applications of Bone Marrow-Derived Stem Cells in Avascular Necrosis of the Hip Current Evidence and Future Directions", American Journal of Biomedicine, vol. 13, no. 1, pp. 34-51.
@article{wejdi2025, title={Therapeutic Applications of Bone Marrow-Derived Stem Cells in Avascular Necrosis of the Hip Current Evidence and Future Directions}, author={Wejdi Abbass Yassin Al-Fatlawy, Nasser Ghaly Yousif}, journal={American Journal of Biomedicine}, volume={13}, number={1}, pages={34-51}, year={2025}, doi={ 10.18081/2333-5106/2025.1/35} }
TY - JOUR AU - Wejdi Abbass Yassin Al-Fatlawy, Nasser Ghaly Yousif TI - Therapeutic Applications of Bone Marrow-Derived Stem Cells in Avascular Necrosis of the Hip Current Evidence and Future Directions JO - American Journal of Biomedicine VL - 13 IS - 1 SP - 34-51 PY - 2025 DO - 10.18081/2333-5106/2025.1/35 ER -
%0 Journal Article %A Wejdi Abbass Yassin Al-Fatlawy, Nasser Ghaly Yousif %T Therapeutic Applications of Bone Marrow-Derived Stem Cells in Avascular Necrosis of the Hip Current Evidence and Future Directions %J American Journal of Biomedicine %V 13 %N 1 %P 34-51 %D 2025 %R 10.18081/2333-5106/2025.1/35 %M
Wejdi Abbass Yassin Al-Fatlawy, Nasser Ghaly Yousif (2025). Therapeutic Applications of Bone Marrow-Derived Stem Cells in Avascular Necrosis of the Hip Current Evidence and Future Directions. American Journal of Biomedicine, 13(1), 34-51. https://doi.org/ 10.18081/2333-5106/2025.1/35

Article metric